CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer

Memo - Magazine of European Medical Oncology

Volumn 6, Issue 2, 2013, Pages 75-82

  Hilbe, Wolfgang ^a   Abacioglu, Ufuk ^b   Aebersold, Daniel M ^c   Bachouchi, Mounir ^d   Brodowicz, Thomas ^e   Gaafar, Rabab ^f   Holzer, Gerold ^e   Mohn Staudner, Andrea ^g   Kalev, Dimitar ^h   Kalinka Warzocha, Ewa ⁱ   Kovac, Viljem ^j   Siano, Marco ^k   Yumuk, Fulden ^l   Tamasi, Lilla ^a,m  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Clinic of Radiation Oncology   (Turkey)

^c UNIVERSITY OF BERN   (Switzerland)

^d Centre d'Oncologie 16 Novembre   (Morocco)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f CAIRO UNIVERSITY   (Egypt)

^g Wiener Krankenanstaltenverbund   (Austria)

^h Multiprofile Hospital for Active Treatment Varna   (Bulgaria)

ⁱ Regional Cancer Center   (Poland)

^j INSTITUTE OF ONCOLOGY   (Slovenia)

^k CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^l MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^m SEMMELWEIS UNIVERSITY   (Hungary)

more..

Author keywords

Bone metastases; Denosumab; Lung cancer; RANK ligand; Skeletal related events

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; PLATINUM COMPLEX; VITAMIN D; ZOLEDRONIC ACID;

ADVANCED CANCER; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE PAIN; CANCER PROGNOSIS; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG SAFETY; DYSPNEA; EXTERNAL BEAM RADIOTHERAPY; GENERAL CONDITION DETERIORATION; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOUTH HYGIENE; ORTHOPEDIC SURGERY; OSTEOPOROSIS; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RESPIRATORY FAILURE; SIDE EFFECT; SKELETAL RELATED EVENT; SOLID TUMOR; SPINAL CORD COMPRESSION; SPINE FRACTURE; TUMOR GROWTH;

EID: 84881368270     PISSN: 18655041     EISSN: 18655076     Source Type: Journal    
DOI: 10.1007/s12254-013-0088-6     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-41.
3. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site. 2011. Accessed 2 Jan 2013.
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s-9.
5. Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res. 2008;466(3):729-36.
6. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer. 2007;57(2):229-32.
7. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613-21.
8. Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer. 2009;65(2):219-22.
9. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168(3):1005-7.
10. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150-7.
11. EMA. 2011 [January 2]; Available from: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/002173/WC500110381.pdf. Accessed 2 Jan 2013.
12. FDA. 2010 [January 2]; Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/125320s007lbl.pdf. Accessed 2 Jan 2013.
13. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-32.
14. Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7(12):1823-9.
15. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, et al. Metastatic non-small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii56-64.
16. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-9.
17. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet. 2011;377(9768):813-22.
18. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomized, phase 3 trials. Eur J Cancer. 2012;48(16):3082-92.
19. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655-64.
20. Kitazawa S, Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol. 2002;198(2):228-36.
21. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584-93.
22. Feeley BT, Liu NQ, Conduah AH, Krenek L, Roth K, Dougall WC, et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res. 2006;21(10):1571-80.
23. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006; 440(7084):692-6.
24. Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther. 2008;7(7):2160-9.
25. Miller R, Jones J, Roudier M, Dougall WC. The RANKL inhibitor OPG-Fc, either alone or in combination with docetaxel, blocks lung cancer-induced osteolytic lesions and reduces skeletal tumor burden in a murine model of non-small cell lung cancer in bone. 9th International Conference on Cancer-Induced Bone Disease;2009; Arlington, VA.
26. Stahel RA, Peters S. ETOP Newsletter October 2012. 2012 [January 17]; Available from: http://www.etop-eu.org.
27. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012; 23(5):1341-7.
28. AAOMS. Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw - 2009 Update. 2009 [January 2]; Available from: http://www.aaoms.org/docs/ position-papers/bronj-update.pdf.
29. Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965-76.
30. Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007;25(11):1423-36.
31. Agarawal JP, Swangsilpa T, van der Linden Y, Rades D, Jeremic B, Hoskin PJ. The role of external beam radiotherapy in the management of bone metastases. Clin Oncol (R Coll Radiol). 2006;18(10):747-60.
32. Hall WA, Stapleford LJ, Hadjipanayis CG, Curran WJ, Crocker I, Shu HK. Stereotactic body radiosurgery for spinal metastatic disease: an evidence-based review. Int J of Surg Oncol. 2011; 2011:979214.
33. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756-65.
34. Fizazi K, Brown JE, Carducci M, Shore ND, Sieber P, Kueppers F, et al. editors. Denosumab in patients with metastatic prostate cancer previously treated with denosumab or zoledronic acid: 2-year open-label extension phase results from the pivotal phase 3 study. European Society of Medical Oncology;2012.
35. Stopeck AT, Lipton A, Martàn M, Body J-J, Paterson A, Steger GG, et al. editors. Denosumab in Patients with Breast Cancer and Bone Metastases Previously Treated with Zoledronic Acid or Denosumab: Results from the 2-Year Open-Label Extension Treatment Phase of a Pivotal Phase 3 Study. San Antonio Breast Cancer Symposium;2011.